Longevity Digest · Special feature
The Longevity Review 2026
A new annual global benchmark from Super Human Network and Boston Consulting Group
More than $21 billion in disclosed investment has flowed into longevity. As longevity moves into commercial products and services, understanding what the evidence supports becomes increasingly important.
The Longevity Review 2026, newly released by Super Human Network and Boston Consulting Group, is a new annual benchmark bringing together the science, investment and consumer behavior shaping the global longevity field.
Built to be an accessible reference point, it examines what research supports, what remains unproven, where investment is flowing, and how people are responding.
The 85-page review brings scientific research, investment analysis and consumer behavior together. It draws on a study of 9,350 people across 19 countries and interviews with 14 experts to examine where the field stands today.
“People are drowning in advice and starving for validated proof.”
Ash Pournouri, Founder & CEO, Super Human Network
Contributors include Dr. David Sinclair, Prof. Andrea Maier, Dr. Jamie Justice and Retro Biosciences co-founder Joe Betts-LaCroix.
The longevity landscape
The science: Explore the biology of aging, the tools used to measure it and the research needed to turn discoveries into treatments.
The investment: Roughly 10% of companies account for around 80% of disclosed deal value. See how capital is distributed across biotech, diagnostics and consumer health.
The outlook: Read individual perspectives on the field’s next phase, from clinical practice to longevity biotech, and the challenges that will shape its development.
For founders, investors and operators, the Review provides context for understanding the science, capital and consumer behavior shaping longevity.
Forward this email to a colleague or partner following the business of longevity.
A Longevity Digest special feature in partnership with Super Human Network.